HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Abstract
A chemotherapy response score (CRS) system was recently described to assess the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy. The current study was performed as an independent assessment of this CRS system. We retrospectively identified advanced stage HGSC patients who received neoadjuvant chemotherapy and underwent interval debulking. If available, a hemotoxylin and eosin slide from the omentum and the adnexa was selected for the study. Slides were independently scored by 13 pathologists using the 3-tiered CRS system. Reviewers then received web-based training and rescored the slides. Overall survival and progression-free survival were estimated using the Kaplan-Meier method and compared using the log-rank test. A total of 68 patients with omental (n=65) and/or adnexal (n=59) slides were included in the study. Interobserver reproducibility was moderate for omentum (κ, 0.48) and poor for adnexa (κ, 0.40), which improved for omentum (κ, 0.62) but not for adnexa (κ, 0.38) after online training. For omental slides, a consensus CRS of 1/2 was associated with a shorter median progression-free survival (10.9 mo; 95% confidence interval, 9-14) than a CRS of 3 (18.9 mo; 95% CI, 18-24; P=0.020). In summary, a 3-tiered CRS system of hemotoxylin and eosin-stained omental deposits can yield prognostic information for HGSC patients receiving neoadjuvant chemotherapy, and web-based training improved reproducibility but did not alter determination of clinical outcomes. The CRS system may allow oncologists to identify potential nonresponders and triage HGSC patients for heightened observation and/or clinical trials.
AuthorsHelena M Ditzel, Kyle C Strickland, Emily E Meserve, Elizabeth Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Michael G Muto, Joyce F Liu, Colleen Feltmate, Neil Horowitz, Ross S Berkowitz, Mamta Gupta, Jonathan L Hecht, Douglas I Lin, Kirsten M Jochumsen, William R Welch, Michelle S Hirsch, Bradley J Quade, Kenneth R Lee, Christopher P Crum, George L Mutter, Marisa R Nucci, Brooke E Howitt
JournalInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists (Int J Gynecol Pathol) Vol. 38 Issue 3 Pg. 230-240 (May 2019) ISSN: 1538-7151 [Electronic] United States
PMID29750700 (Publication Type: Journal Article, Validation Study)
Topics
  • Adnexa Uteri (pathology, surgery)
  • Aged
  • Carcinoma (diagnosis, drug therapy, pathology, surgery)
  • Cytoreduction Surgical Procedures
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Neoadjuvant Therapy
  • Observer Variation
  • Omentum (pathology, surgery)
  • Online Systems
  • Ovarian Neoplasms (diagnosis, drug therapy, pathology, surgery)
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: